Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced that Regeneron has terminated the option and license agreement collaboration between the companies.
Novartis reported the first interpretable results of the Phase III KITE study, assessing the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular edema (DME).